Vimta Labs Ltd-$ — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Vimta Labs reported Q1 FY27 total income of INR1,129 million, up 13.7% year-on-year, with EBITDA of INR411 million and PAT of INR210 million. Management said pharma contract research and testing grew year-on-year while food testing declined due to weaker import-export sample receipts linked to global trade challenges. The company secured and onboarded its first Biologics services order during the quarter and outlined an approximately INR80 crore capex plan for FY27.
Vimta Labs reported Q4 FY'26 total income of INR1,120 million, up 16.6% year-on-year, with EBITDA of INR421 million and PAT of INR211 million. For the full year FY'26, total income rose 19.5% to INR4,163 million with EBITDA margin at 35.8% and PAT margin at 18.6%. Management discussed the entry into biologics contract research services, export revenue of around 38% in Q4, and commented on the impact of geopolitical tensions and tariffs on input costs and supply chains.